Physician profile
David Carney
NPI 1245282094
$1,461.28
in general payments reported to CMS, 2019-2025
22 companies · $621 in 2025
The $621 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $308 · 2020: $63.29 · 2021: $43.54 · 2022: $67.07 · 2023: $56.68 · 2024: $302 · 2025: $621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $979.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $979.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $209.40 | 2019-2025 | |
| Abbvie INC. | $176.69 | 2021-2025 | Ubrelvy |
| Novo Nordisk INC | $175.36 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Sumitomo Pharma America, INC. | $105.81 | 2025 | Gemtesa, Orgovyx |
| Janssen Pharmaceuticals, INC | $89.85 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $89.77 | 2019-2025 | Farxiga |
| Exact Sciences Corporation | $84.72 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $77.67 | 2022-2025 | Gardasil 9, Capvaxive, Gardasil |
| Verona Pharma, INC. | $72.95 | 2025 | Ohtuvayre |
| Amgen INC. | $70.79 | 2019-2025 | Otezla, Repatha, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.88 | 2019-2025 | Xifaxan |
| Digital Diagnostics INC. | $38.99 | 2020 | |
| Viatris Specialty LLC | $30.94 | 2025 | Yupelri |
| Vertex Pharmaceuticals Incorporated | $26.99 | 2025 | |
| Glaxosmithkline, LLC. | $24.98 | 2025 | Shingrix, Arexvy |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $24.30 | 2020 | |
| Tolmar, INC. | $22.98 | 2025 | Eligard, Jatenzo |
| Sanofi Pasteur INC. | $22.51 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $18.47 | 2024 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.00 | 2019 | |
| Lilly USA, LLC | $13.92 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Carney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.